Hemo Organic Limited

As of June 30, 2026, Hemo Organic Limited carries a market capitalization of 74.59M, placing it among publicly traded companies globally. Its enterprise value stands at 74.59M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Hemo Organic Limited has 3.53M shares outstanding.

These figures are as of June 30, 2026.

These figures are as of June 30, 2026. The EV/Sales ratio of 8.05 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 74.59M versus a market cap of 74.59M, with the gap driven by net debt and cash on the balance sheet.

Over the twelve months ended June 30, 2026, Hemo Organic Limited recorded 3.09M in income tax expense. The company reported a pretax loss of -4.58M and -7.67M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 19, 2026, Hemo Organic Limited's stock has gained approximately 182.88% over the past 52 weeks. The 50-day moving average sits at 17.80, while the 200-day moving average is 14.18.

Over the twelve months ended June 30, 2026, Hemo Organic Limited generated 9.27M in revenue and converted that into -7.67M in net income, yielding earnings per share of -2.21. EBITDA reached -4.59M, while operating income came in at -4.60M.

Over the twelve months ended June 30, 2026, Hemo Organic Limited posted a gross margin of -0.09, reflecting its pricing power and cost economics. The operating margin of -49.62 and net profit margin of -82.69 provide insight into operational efficiency.